Abstract
An increasing number of scales used to assess Parkinson’s disease (PD) motor manifestations (tremor, rigidity, bradykinesia) and disability have been developed in the past years. However, some of them lack appropriate validation. In this chapter, the most widely used and tested scales to assess motor manifestations and disability are discussed.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
- Motor Complication
- Abnormal Involuntary Movement Scale
- Nonmotor Symptom
- Clinimetric Property
- Gait Evaluation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Marinus J, Visser M, Stiggelbout AM, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatr. 2004;75:388-395.
Martinez-Martin P, Benito-Leon J, Burguera JA, et al. The SCOPA-Motor Scale for assessment of Parkinson’s disease is a consistent and valid measure. J Clin Epidemiol. 2005;58:674-679.
Forjaz MJ, Carod FJ, Virues J, et al. The SCOPA motor scale in Latin-America: Metric properties. Mov Disord. 2007;22:S193.
Wilson RE, Seeberger LC, Buck PO, et al. Investigation of the psychometric properties of the short Parkinson’s evaluation scale/scales for outcomes in Parkinson’s disease (SPES/SCOPA). Mov Disord. 2010;25:S348.
Schwab JF England AC. Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson’s Disease. Edinburgh, Scotland: E & S Livingston. 1969;152-157
McRae C, Diem G, Vo A, et al. Schwab & England: Standardization of administration. Mov Disord. 2000;15:335-336.
Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17:867-876.
Martinez-Martin P, Forjaz MJ. Metric attributes of the unified Parkinson’s disease rating scale 3.0 battery: Part I, feasibility, scaling assumptions, reliability, and precision. Mov Disord. 2006;21:1182-1188.
Martinez-Martin P, Prieto L, Forjaz MJ. Longitudinal metric properties of disability rating scales for Parkinson’s disease. Value Health. 2006;9:386-393.
Forjaz MJ, Martinez-Martin P. Metric attributes of the unified Parkinson’s disease rating scale 3.0 battery: part II, construct and content validity. Mov Disord. 2006;21:1892-1898.
Stebbins GT, Goetz CG. Factor structure of the Unified Parkinson’s Disease Rating Scale: Motor Examination section. Mov Disord. 1998;13:633-636.
Martinez-Martin P, Gil-Nagel A, Morlan Gracia L, et al. Intermediate scale for assessment of Parkinson’s disease. Characteristics and structure. Parkinsonism Relat Disord. 1995;1:97-102.
Martinez-Martin P, Garcia Urra D, del Ser Quijano T, et al. A new clinical tool for gait evaluation in Parkinson’s disease. Clin Neuropharmacol. 1997;20:183-194.
Martinez-Martin P, Cubo E. Scales to measure parkinsonism. In: Koller W, Melamed E, eds. Handbook of Clinical Neurology: Parkinson’s Disease and Related Disorders, Part I. Edinburgh:Elsevier; 2007:291-327.
Molina J, Gonzalez de la Aleja J, Bermejo-Pareja F, Martinez-Martin P. Trastornos del movimiento. I. Enfermedad de Parkinson y parkinsonismos. In: Bermejo-Pareja F, Porta-Etessam J, Diaz-Guzman J, Martinez-Martin P, eds. Más de cien escalas en Neurología. Madrid: Aula Medica; 2008:183-224.
Serrano-Duenas M, Calero B, Serrano S, et al. Psychometric attributes of the rating scale for gait evaluation in Parkinson’s disease. Mov Disord. 2010;25:2121-2127.
O’Sullivan JD, Said CM, Dillon LC, et al. Gait analysis in patients with Parkinson’s disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord. 1998;13:900-906.
Guy W. Abnormal Involuntary Movement Scale. ECDEU Assessment manual for psychopharmacology. Revised. Rockville, MD: National Institure of Mental Health, US Department of Health, Education and Welfare; 1976.
Colosimo C, Martinez-Martin P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations. Mov Disord. 2010;25:1131-1142.
Whall AL, Engle V, Edwards A, et al. Development of a screening program for tardive dyskinesia: feasibility issues. Nurs Res. 1983;32:151-156.
Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci. 1993;5:56-60.
Katzenschlager R, Schrag A, Evans A, et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology. 2007;69:555-563.
Hoff JI, Van den Plas AA, Wagemans EA, Van Hilten JJ. Accelerometric assessment of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2001;16:58-61.
Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord. 2005;20:224-230.
Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22:179-186.
Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord. 2002;17:372-377.
Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson’s disease: inter- and intrarater reliability assessment. Mov Disord. 1994;9:390-394.
Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS ONE. 2010;5:e15298.
Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology. 1989;39(suppl 2):11-19.
Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726-733.
Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition of motor and nonmotor wearing-off in Parkinson’s disease. J Neural Transm. 2007;114:211-217.
Stacy MA, Murphy JM, Greeley DR, et al; for the COMPASS-I Study Investigators. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord. 2008;14:205-212.
Martinez-Martin P, Hernandez B. The Q10 questionnaire for detection of wearing-off phenomena in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:382-385.
Santens P, De Noordhout AM. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson’s disease using a dedicated questionnaire: a Belgian multicenter survey. Acta Neurol Belg. 2006;106:137-141.
Martinez-Martin P, Tolosa E, Hernandez B, Badia X. The Patient Card questionnaire to identify wearing-off in Parkinson disease. Clin Neuropharmacol. 2007;30:266-275.
Abbruzzese G, Antonini A, Barone P, et al. Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson’s disease. Neurol Sci. 2012;33:1319-1327.
Silburn PA, Mellick GD, Vieira BI, Danta G, Boyle RS, Herawati L. Utility of a patient survey in identifying fluctuations in early stage Parkinson’s disease. J Clin Neurosci. 2008;15:1235-1239.
K, et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility–an open-label, 6-week study. J Neural Transm. 2010;117:333-342.
Litvinenko IV, Odinak MM, Mogil’naia VI, Sologub OS, Sakharovskaia AA. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson’s disease: results of an open-label clinical study]. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109:51-54.
Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:57-61.
Martinez-Martin P, Tolosa E, Hernandez B, Badia X; for the ValidQUICK Study Group. Validation of the “QUICK” questionnaire—A tool for diagnosis of “wearing-off” in patients with Parkinson’s disease. Mov Disord. 2008;23:830-836.
Azulay JP, Durif F, Rogez R, Tranchant C, Bourdeix I, Rerat K. [Precoce survey: a new self-assessment patient card for early detection and management of Parkinson disease fluctuations]. Rev Neurol (Paris). 2008;164:354-362.
Chan A, Cheung YF, Yeung MA, et al. A validation study of the Chinese wearing off questionnaire 9-symptom for Parkinson’s disease. Clin Neurol Neurosurg. 2011;113:538-540.
Kondo T, Takahashi K. [Translation and linguistic validation of the Japanese version of the wearing-off questionnaires(WOQ-19 and WOQ-9)]. Brain Nerve. 2011;63:1285-1292.
Bareš M, Rektorova I, Jech R, et al. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease? J Neural Transm. 2012;119:373-380.
Stacy M. The wearing-off phenomenon and the use of questionnaires to facilitate its recognition inParkinson’s disease. J Neural Transm. 2010;117:837-846.
Antonini A, Martinez-Martin P, Chaudhuri RK, et al. Wearing-off scales in Parkinson’s disease: Critique and recommendations. Mov Disord. 2011;26:2169-2175.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Healthcare
About this chapter
Cite this chapter
Martinez-Martin, P., Rodriguez-Blazquez, C., Forjaz, M.J., Chaudhuri, K.R. (2014). Motor Impairment and Disability Scales. In: Guide to Assessment Scales in Parkinson’s Disease. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-88-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-907673-88-7_4
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-907673-87-0
Online ISBN: 978-1-907673-88-7
eBook Packages: MedicineMedicine (R0)